CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Naproxendrug
Likely dose
Naproxen 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03697720
NCT03697720Phase 4Completed
CompareCT.gov

Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

Endeavor Health·interventional·Posted Oct 5, 2018·Updated Oct 18, 2023

In Brief

A Phase 4 clinical trial evaluating Naproxen for Dysmenorrhea and Pain. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The goal of this study is to see if optimized use of naproxen for treatment of dysmenorrhea will improve pain report from baseline. In addition, we will determine whether cross-organ influences from the uterus on bladder pain sensitivity change from baseline after reduced menstrual pain experience over six months. Finally, a battery of quantitative sensory tests and EEG measures of sensory sensitivity will be used to evaluate mechanisms associated with improvements in menstrual and bladder pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysmenorrhea, Pain
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 5, 2018
Enrollment StartMay 9, 2018
Primary CompletionNov 23, 2020
Study CompletionSep 27, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago

Interventions

Naproxendrug

Participants will take naproxen 500mg BID before and for the first 3 days of their period.